← All Cg Oncology, INC filings

Cg Oncology, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares
Leonard E Post, a Director of CG Oncology, Inc., sold 1,000 shares of common stock on July 15, 2026 for $71.17 per share.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares
James Mulay, a Director of CG Oncology, Inc., sold 24,165 shares of common stock on July 10, 2026 for $75.16 per share.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Acquires Shares
CG Oncology, Inc. reports a significant acquisition of common stock by Director Brian Guan-Chyun Liu.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares Under 10b5-1 Plan
CG Oncology Director Leonard E. Post has sold 5,000 shares of common stock, valued at approximately $350,000, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: Director James Mulay Executes CG Oncology Stock Options
Director James Mulay exercised stock options and sold the resulting shares of CG Oncology, Inc. under a 10b5-1 plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Receives Stock Option Grant
Director Victor Edward Tong Jr. was granted 9,354 stock options in CG Oncology, Inc. as part of a standard equity incentive.
NASDAQ
CGON
Cg Oncology, INC
Form 4: Director James Mulay Receives Equity Grant at CG Oncology
Director James Mulay was granted 9,354 stock options in CG Oncology, Inc. as part of a standard equity compensation arrangement.
NASDAQ
CGON
Cg Oncology, INC
Form 4: Director Christina Rossi Receives CG Oncology Stock Options
CG Oncology director Christina Rossi was granted 9,354 stock options as part of standard equity compensation.
NASDAQ
CGON
Cg Oncology, INC
Form 4: Director Leonard Post Executes Stock Option Plan
Director Leonard Post exercised 1,000 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: Director James Mulay Executes CG Oncology Stock Sale
Director James Mulay exercised options to acquire 15,600 shares of CG Oncology and subsequently sold them under a 10b5-1 plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology COO Ambaw Bellete Receives Stock Options
CG Oncology President and COO Ambaw Bellete was granted 107,508 employee stock options with an exercise price of $67.68.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology CMO Vijay Kasturi Receives Stock Options
Chief Medical Officer Vijay Kasturi was granted 79,216 employee stock options in CG Oncology, Inc. on April 15, 2026.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology GC Joshua Patterson Receives Stock Options
General Counsel and Chief Compliance Officer Joshua F. Patterson was granted 45,266 employee stock options by CG Oncology, Inc.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology CFO James DeTore Receives Stock Options
CG Oncology CFO James DeTore was granted 90,574 employee stock options with an exercise price of $67.68.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology CEO Arthur Kuan Receives Stock Option Grant
CG Oncology CEO Arthur Kuan was granted 271,600 employee stock options with an exercise price of $67.68.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares Via 10b5-1 Plan
CG Oncology Director James Mulay exercised stock options and sold 1,964 shares of common stock for approximately $124,714 under a pre-arranged 10b5-1 trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology CEO Exercises Options, Boosts Direct Holdings
CG Oncology's CEO, Arthur Kuan, exercised stock options to acquire 62,765 net shares of common stock, increasing his direct beneficial ownership.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology CEO Exercises Stock Options
CG Oncology's CEO, Arthur Kuan, exercised 102,871 stock options, acquiring 100,000 net shares through a cashless exercise.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares After Option Exercise
CG Oncology Director James Mulay executed a pre-planned sale of common stock following the exercise of stock options on January 9, 2026.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Granted Stock Options
CG Oncology director Christina Rossi received 20,889 stock options with a vesting schedule commencing November 24, 2025.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology director sells 1,000 shares via 10b5-1
Director Leonard E. Post exercised 1,000 options at $0.6 and sold 1,000 shares at $41.43 on November 17, 2025 under a pre-set Rule 10b5-1 plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares Under 10b5-1 Plan
CG Oncology Director Leonard Post exercised options and sold 1,000 shares of common stock for $43.25 per share under a pre-arranged trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares After Option Exercise
CG Oncology Director James Mulay exercised stock options and subsequently sold 5,903 shares of common stock for $43.99 per share.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares After Option Exercise
CG Oncology Director Leonard Post exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares After Option Exercise
CG Oncology Director James Mulay exercised stock options and subsequently sold 12,755 shares of common stock for a weighted average price of $39.19 per share.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CGON Director Sells Shares After Option Exercise
CG Oncology Director James Mulay exercised stock options and subsequently sold the acquired common stock in pre-planned transactions on September 18 and 19, 2025.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CGON Director Sells Shares After Option Exercise
CG Oncology Director Leonard Post exercised options and sold 1,000 shares of common stock for a profit, pursuant to a pre-arranged trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director's Firm Buys $50M in Shares
A firm managed by CG Oncology Director Brian Guan-Chyun Liu acquired 1,515,151 shares of common stock for approximately $50 million.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CG Oncology Director Sells Shares After Option Exercise
CG Oncology Director James Mulay exercised stock options and subsequently sold all acquired shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
CGON
Cg Oncology, INC
Form 4: CGON Director Sells $2.7M in Shares Under 10b5-1 Plan
CG Oncology Director and 10% owner Hong Fang Song sold 99,999 shares of common stock for approximately $2.7 million through pre-arranged trading plans.